Abstract
The advent of thoracic endovascular aortic repair (TEVAR) has resulted in improved morbidity and mortality for patients compared with open thoracic aortic repair. Yet it remains unclear how chronic kidney disease (CKD) affects TEVAR outcomes. The paucity of data on CKD patients can be rectified using the robust vascular-specific Vascular Quality Initiative. This study's goal was to identify adverse outcomes associated with CKD stage including postoperative 30-day outcomes and 1-year survival after TEVAR for aortic aneurysm.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
